New inhibitors of the bacterial transferase MraY from (MraY), based on the aminoribosyl uridine central core of known natural MraY inhibitors, have been designed to generate interaction of their oxadiazole linker with the key amino acids (H324 or H325) of the enzyme active site, as observed for the highly potent inhibitors carbacaprazamycin, muraymycin D2 and tunicamycin. A panel of ten compounds was synthetized notably thanks to a robust microwave-activated one-step sequence for the synthesis of the oxadiazole ring that involved the -acylation of an amidoxime and subsequent cyclization. The synthetized compounds, with various hydrophobic substituents on the oxadiazole ring, were tested against the MraY transferase activity. Although with poor antibacterial activity, nine out of the ten compounds revealed the inhibition of the MraY activity in the range of 0.8 µM to 27.5 µM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495235 | PMC |
| http://dx.doi.org/10.3390/antibiotics11091189 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In vivo divergent evolution of cross-resistance to new β-lactam/β-lactamase inhibitor combinations in Pseudomonas aeruginosa following ceftazidime/avibactam treatment.
Infection
November 2024
Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Purpose: To describe and characterize the evolutionary process of cross-resistance to ceftazidime/avibactam, ceftolozane/tazobactam and imipenem/relebactam of a carbapenem-resistant Pseudomonas aeruginosa (CRPA) lineage isolated from a patient receiving two courses of ceftazidime/avibactam treatment.
Methods: The minimum inhibitory concentrations (MICs) of strains were determined by broth microdilution methods. The mutant genes were identified by the whole genome sequencing results.
Theoretical investigation of the effects of diverse hydrogen-bonding characteristics on the O chemical shielding and electric field gradient tensors within the active sites of MraY bound to nucleoside antibiotics capuramycin, carbacaprazamycin, 3'-Hydroxymureidomycin A, and muraymycin D2.
Solid State Nucl Magn Reson
October 2024
Drug Design and Bioinformatics Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, 13169-43551, Iran.
Article Synopsis
- This study builds on previous research to analyze how hydrogen bonds and charge transfer interactions impact the chemical properties of oxygen in various MraY-inhibitor complexes using advanced computational methods.
- The findings reveal that the nuclear shielding of carboxylate and carbonyl oxygens increases with shorter hydrogen bond lengths and higher p-character in charge transfer interactions, while hydroxyl oxygens experience a deshielding effect under similar conditions.
- The calculated parameters align well with experimental data, providing insights into the relationship between NMR spectroscopy and hydrogen bonding in protein-ligand interactions.
Tunicamycins from Marine-Derived Inhibit MurNAc-Pentapeptide Translocase in .
Mar Drugs
June 2024
Department of Agricultural Biotechnology, College of Agriculture and Life Sciences and Natural Products Research Institute, Seoul National University, Seoul 08826, Republic of Korea.
Article Synopsis
- Four tunicamycin compounds were identified from a marine actinomycete strain, revealing their potential as antibacterial agents.
- The compounds demonstrated strong activity against Gram-positive bacteria, with minimum inhibitory concentration (MIC) values between 0.13-0.25 µg/mL.
- They were found to inhibit the MraY enzyme, crucial for bacterial cell wall synthesis, with inhibitory concentrations (IC) ranging from 0.08-0.21 µg/mL.
Development of a natural product optimization strategy for inhibitors against MraY, a promising antibacterial target.
Nat Commun
June 2024
Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, 060-0812, Japan.
Article Synopsis
- MraY inhibitory natural products are promising candidates for new antibacterial treatments, especially against drug-resistant bacteria, but improving their properties through chemical modifications is challenging due to complex synthesis processes.
- A new strategy has been developed to efficiently create and evaluate a library of 686 MraY analogue compounds, allowing for streamlined preparation and direct assessment of their biological activities.
- This research identifies several potent analogues that are effective against drug-resistant strains and reveals unique binding patterns with MraY, while also demonstrating the method's applicability to other natural products targeting tubulin activities.
The MraY Inhibitor Muraymycin D2 and Its Derivatives Induce Enlarged Cells in Obligate Intracellular and and Break the Persistence Phenotype in .
Antibiotics (Basel)
May 2024
Institute for Pharmaceutical Microbiology (IPM), University of Bonn, University Hospital Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany.
Chlamydial infections and diseases caused by filarial nematodes are global health concerns. However, treatment presents challenges due to treatment failures potentially caused by persisting and long regimens against filarial infections accompanied by low compliance. A new treatment strategy could be the targeting of the reduced peptidoglycan structures involved in cell division in the obligate intracellular bacteria and , the latter being obligate endosymbionts supporting filarial development, growth, and survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!